To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Kestrel sells portfolio company to Pfizer Animal Health
Sydney-based Kestrel Capital has sold its stake in Catapult Genetics, making a 2.5x cash return on its investment in three years.
